POR | Transition Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma– Our Histopathological and Clinical Experience With Patients With Intermediate Lymphoma
B cell depletion therapies in autoimmune disease: advances and mechanistic insights | Nature Reviews Drug Discovery
CD20 alternative transcripts code for an intracellular CD20 protein.... | Download Scientific Diagram
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy | Haematologica
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. - Abstract - Europe PMC
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing - ScienceDirect
Immunohistochemistry and Flow Cytometry in Bone Marrow Haematopathology (Chapter 19) - Diagnostic Bone Marrow Haematopathology
Cd marker handbook
Frontiers | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going? | Immunology
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies | Clinical Cancer Research
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys | Scientific Reports
Antibody panel selection and lineage differentiation. In Bcell acute... | Download Scientific Diagram
Cd marker handbook
Immunohistochemical localization of CD3, CD4, CD8, CD20 and CD68 in... | Download Scientific Diagram
Cd marker handbook
CD20-positive T-cell lymphoma involving bone marrow: report of four cases | SpringerLink
Pan Lymphoma cocktail Antibody- Biocare Medical
Detection of subsets of CD3+CD20+ T cells in healthy subjects. (A) (i)... | Download Scientific Diagram
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing - EBioMedicine
Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. - Abstract - Europe PMC
Frontiers | Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells | Immunology